Guide to the correct usage and dosage of the new anti-cancer drug Platinib

Pralsetinib (Pralsetinib), a highly efficient and selective RET tyrosine kinase inhibitor, has achieved remarkable results in the treatment of non-small cell lung cancer (NSCLC) and RET-mutated medullary thyroid cancer (MTC) in recent years. However, to fully exert its efficacy and reduce adverse reactions, patients must strictly follow the doctor's instructions and the usage and dosage in the drug instructions.

Platinib is administered orally, once daily, and the recommended dose is 400 mg each time. This dose is based on the optimal dose range determined through extensive clinical trials and pharmacokinetic studies. To ensure the best absorption and effect of the drug, patients should take it on an empty stomach, that is, fast for at least 2 hours before and after taking the drug and 1 hour before and after taking the drug.

During the medication process, patients need to pay close attention to their own reactions and maintain close communication with their doctors. If you accidentally miss a dose, you should take it as soon as possible on the same day. However, if vomiting occurs after taking the medicine, there is no need to take additional doses and you can continue to take the next dose as originally planned. Doctors may adjust the drug dosage accordingly based on the patient's treatment response and adverse reactions. If reducing the dose to the minimum daily 100 mg is still intolerable, permanent discontinuation may be considered.

Platinib is in capsule form. It should be swallowed whole with a full glass of water and should not be broken, chewed or dissolved. For patients who require long-term treatment, it is recommended to take it at a fixed time every day to maintain stable blood concentration. At the same time, simultaneous use with certain drugs, especially potent CYP3A inducers or inhibitors, should be avoided to avoid interfering with the metabolism and efficacy of platinib.

It is worth noting that platinib may cause a series of adverse reactions, such as hypertension, neutropenia, and elevation of aspartate aminotransferase. Therefore, before starting treatment, patients should undergo a comprehensive physical examination and evaluation to ensure that they are physically fit to receive this drug. In addition, women of childbearing age should take effective non-hormonal contraceptive measures while taking the medicine and within 1 week after stopping the medicine; men with female partners should also take corresponding contraceptive measures while taking the medicine and within 1 week after stopping the medicine.

In short, the usage and dosage of platinib must strictly follow the doctor's instructions and the guidance in the drug package insert. Patients should pay close attention to their own reactions during medication and maintain close communication with their doctors to ensure the best efficacy of the medication and reduce the occurrence of adverse reactions. At the same time, patients should also fully understand the possible adverse reactions and contraindications caused by platinib so that they can handle it in time when abnormal situations occur. Patients should make their own decisions when choosing a drug version, but be sure to purchase it through formal and reliable channels to ensure the quality and safety of the drug.